We assessed the cardiovascular safety of long-term direct-acting oral anticoagulant (DOAC) treatment. A search of the medical literature was performed from inception until May 31, 2019. Inclusion criteria were (1) randomized trial that assessed the clinical efficacy and/or safety of 1 or more DOAC, (2) control group including oral anticoagulation and/or antiplatelet and/or placebo treatment, and (3) the incidence of acute coronary syndrome during follow-up was reported. Fixed-effect and random-effects models were applied. The analyzed outcomes were myocardial infarction (MI), major bleeding, and mortality. Twenty-eight randomized clinical trials (196 761 patients) were included. Rivaroxaban was associated with a 21% reduction in the relative risk of MI when compared to placebo (relative risk [RR]: 0.79 [95% credible interval, CrI: 0.65-0.94]) and a 31% reduction (RR: 0.70 [95% CrI: 0.53-0.89]) when compared to dabigatran. Apixaban resulted in 24% (RR: 0.76 [95% CrI: 0.58-0.99]) and vitamin K antagonists anticoagulation resulted in 19% (RR: 0.81 [95% CrI: 0.65-0.98]) risk reduction compared to dabigatran. The computed probability of being the first best choice of treatment was 61.8% for rivaroxaban. Cardiovascular safety shows considerable heterogeneity among oral anticoagulants. Treatment with rivaroxaban is associated with reduced rate of MI.
BarnesGDAgenoWAnsellJKaatzS. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(6):1154–56.
2.
CaldeiraDBarraMPintoFJFerreiraJJCostaJ. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol. 2015;262(3):516–22.
3.
CaldeiraDRodriguesFBBarraM, et al.Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015;101(15):1204–11.
4.
VranckxPValgimigliMHeidbuchelH. The significance of drug–drug and drug–food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev. 2018;7(1):55–61.
5.
HuismanMVRothmanKJPaquetteM, et al.The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol. 2017;69(7):777–85.
6.
RothGAHuffmanMDMoranAE, et al.Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132(17):1667–78.
7.
MembersAFWindeckerSKolhP, et al.2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541–19.
8.
AnandSSYusufS. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 Suppl S):62S–9S.
9.
MegaJLBraunwaldEWiviottSD, et al.Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.
10.
EikelboomJWConnollySJBoschJ, et al.Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–30.
11.
UchinoKHernandezAV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402.
12.
DevereauxPJDuceppeEGuyattG, et al.Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018;391(10137):2325–34.
13.
ThygesenKAlpertJSWhiteHD, et al.Universal definition of myocardial infarction. Circulation. 2007;116(22):2634–53.
14.
ThygesenKAlpertJSJaffeAS, et al.Third universal definition of myocardial infarction. Circulation. 2012;126(16):2020–35.
15.
The Nordic Cochrane Centre. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. 2014.
16.
RileyRDJacksonDSalantiG, et al.Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. BMJ. 2017;358:j3932.
17.
LunnDJThomasABestNSpiegelhalterD.WinBUGS—A Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10(4):325–37.
18.
BrownSHuttonBCliffordT, et al.A microsoft-excel-based tool for running and critically appraising network meta-analyses-an overview and application of NetMetaXL. Syst Rev. 2014;3:110.
19.
WallaceBCDahabrehIJTrikalinosTALauJTrowPSchmidCH. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49:1–15.
20.
GrangerCBAlexanderJHMcMurrayJJV, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
21.
GiuglianoRPRuffCTBraunwaldE, et al.Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
22.
ConnollySJEikelboomJJoynerC, et al.Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.
23.
HoriMMatsumotoMTanahashiN, et al.Rivaroxaban vs. warfarin in japanese patients with atrial fibrillation. Circ J. 2012;76(9):2104–11.
24.
GibsonCMMehranRBodeC, et al.Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–34.
25.
CannonCPBhattDLOldgrenJ, et al.Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.
26.
ConnollySJEzekowitzMDYusufS, et al.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
27.
PatelMRMahaffeyKWGargJ, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.
28.
CappatoREzekowitzMDKleinAL, et al.Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346–55.
29.
GoetteAMerinoJLEzekowitzMD, et al.Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995–2003.
30.
EzekowitzMDPollackC V.HalperinJL, et al.Apixaban compared to heparin/Vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959–71.
31.
HartRGSharmaMMundlH, et al.Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191–201.
32.
DienerH-CSaccoRLEastonJD, et al.Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906–17.
33.
AgnelliGBullerHRCohenA, et al.Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
34.
WeitzJILensingAWAPrinsMH, et al.Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211–22.
35.
ScottDBrennerBBullerHR, et al.Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.
36.
BüllerHRPrinsMHLensinAW, et al.Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97.
37.
InvestigatorsTHV. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–15.
38.
SchulmanSKearonCKakkarAK, et al.Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.
39.
SchulmanSKakkarAKGoldhaberSZ, et al.Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–72.
40.
SchulmanSKearonCKakkarAK, et al.Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–18.
41.
ZannadFAnkerSDByraWM, et al.Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379(14):1332–42.
42.
LopesRDHeizerGAronsonR, et al.Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24.
43.
AlexanderJHLopesRDJamesS, et al.Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708.
44.
KomócsiAVorobcsukAKehlDAradiD. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(20):1537–45.
45.
HohnloserSHOldgrenJYangS, et al.Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized evaluation of long-term anticoagulation therapy) trial. Circulation. 2012;125(5):669–76.
46.
LarsenTBRasmussenLHSkjøthF, et al.Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61(22):2264–73.
47.
LarsenTBRasmussenLHGorst-RasmussenA, et al.Myocardial ischemic events in “real world” patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med. 2014;127(4):329–36.
48.
LeeCJ-YGerdsTACarlsonN, et al.Risk of myocardial infarction in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2018;72(1):17–26.
49.
PerkJDe BackerGGohlkeH, et al.European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2012;33(13):1635–701.
50.
MakKH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):pii: e001592.
51.
OldgrenJWallentinLAlexanderJH, et al.New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013;34(22):1670–80.
52.
LokeYKPradhanSYeongJKKwokCS, Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014;78(4):707–17.
53.
López-LópezJASterneJACThomHHZ, et al.Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;358:j5058.
54.
MorimotoTCrawfordBWadaKUedaS.Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias from open label studies. J Cardiol. 2015;66(6):466–74.
55.
TornyosAKehlDD’AscenzoFKomocsiA. Risk of myocardial infarction in patients with long-term non-vitamin k antagonist oral anticoagulant treatment. Prog Cardiovasc Dis. 2016;58(5):483–94.
56.
HylekEMGoASChangY, et al.Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019–26.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
